View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Clin Rheumatol 2024;43(3):1045–1052 doi: 10.1007/s10067-023-06849-5
The results of the meta-analysis show that TNFi, IL-17i, and JAK inhibitor treatments significantly improved sacroiliac joint SPARCC scores in patients with axSpA or AS at Weeks 12–16. However, there were no significant differences in mean improvement between the treatment groups.
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead598 Epub ahead of print
This systematic literature review and network meta-analysis provides evidence for bimekizumab being an efficacious option in the management of both b/tsDMARD-naïve and experienced patients across the axSpA spectrum, with similar safety and tolerability to existing treatments.
Arthritis Research & Therapy (2023) 25:70 https://pubmed.ncbi.nlm.nih.gov/37118833/
This real-world study showed that sustained BASDAI <3 may be a valid and feasible target for a treat-to-target strategy in AxSpA, having function as treatment goal.
Autoimmunity Reviews 22 (2023) 103357
The study demonstrated that obesity is a factor that could play a role in treatment decision-making in people living with inflammatory arthritis (IA). It appears that efficacy of TNFi is affected by patients’ weight/BMI in all forms of IA, while this is not the case for TCZ and ABA in RA, as well for IL-17 and IL-23 inhibitors in PsA.
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
Semin Arthritis Rheum. 2022 doi: 10.1016/j.semarthrit.2022.151979
The authors reviewed drug survival of therapies across common inflammatory skin and joint conditions from national registries. The findings highlighted that despite the overlapping pathogenesis of these conditions there was little similarity in drug survival. This reinforces the need for an individualised treatment approach consistent with the underlying disease, patient profile and treatment history.
Nat Rev Rheumatol. 18, 205–216 (2022) 2022 doi: 10.1038/s41584-022-00761-z
In this review Danve and Deodhar report an update on modern axSpa treatment. They found that in the past two decades substantial progress in the diagnosis and management of axSpA has been witnessed. Whilst ASAS classification criteria have enabled earlier diagnosis the increased availability of novel therapies, evolving drug safety data and novel clinical trials have allowed clinicians to rethink the placement and timing of drugs in disease management.
Inflammopharmacology. 2022, Apr;30(2):435-451. doi: 10.1007/s10787-022-00933-z
The most common immune system-related AEs in patients treated with IL-17 inhibitors are mucosal and opportunistic infections.
Interleukin (IL)-17 inhibitors are a series of biological drugs used to treat a number of conditions, including ankylosing spondylitis, a disease characterised by immune system dysregulation and joint inflammation. Azadeh, et al. aimed to assess the risk of immune system-related AEs due to targeting IL-17 or IL-17R.
